KPTI News and Press, Karyopharm Therapeutics Inc. From 02/02/21

We share the remaining top pick ideas from our Marketplace contributors. There are a wide variety - including biotech, precious metals, dividend, and energy ideas. Later on this week we will share the public Google Sheet that will track the performance of these ideas in real-time....

A support level has formed in the chart of Karyopharm Therapeutics Inc (KPTI). If the stock moves under this level, a breakdown could soon occur. Read more to learn to how to take advantage of this trade. A key support level has emerged in the chart of Karyopharm Therapeutics Inc ( KPTI )...

KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ...

Karyopharm Therapeutics (KPTI) shares climbs 5% in premarket after the European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending the conditional approval for multiple myeloma treatment, Nexpovio (selinexor) in combination with dexam...

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma -- European Commission Decision Anticipated by April 2021 -- PR Newswire NEWTON, Mass. , Jan. 29, 2021 /PRNewswire/ -- ...

Our Roundtable series continues with a focus on biotech and healthcare investing. Apart from COVID-19 and vaccines, opportunities abound. The series will end this week with growth/tech investing and macro and technical analysis. For further details see: 2021 Roundtable: ...

Karyopharm Therapeutics ([[KPTI]] -8.0%) expects total Q4 revenues to be between $35M-36M and between $108M-109M for the FY of 2020, including net product sales for XPOVIO.Additionally, company expects net product sales of XPOVIO to be between $20M-20.5M during Q4 and between $76M- -76.5...

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update -- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Ye...

Antengene has submitted an Investigational New Drug ((IND)) application for ATG-010 (selinexor, XPOVIO) being co-developed by Karyopharm Therapeutics (KPTI)  to the National Medical Products Administration ((NMPA)) in the treatment of Endometrial Cancer.The Phase 3, d...

Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...